LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
LFCR$6.37+0.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial statements
Table of contents
| Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 | 2 | |
| Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and February 23, 2025 | 3 | |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three Months Ended March 31, 2026 and February 23, 2025 | 4 | |
| Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and February 23, 2025 | 5 | |
| Notes to the Consolidated Financial Statements | 6 | |
| 1 | Organization, basis of presentation and summary of significant accounting policies | 6 |
| 2 | Income or loss per share | 8 |
| 3 | Segment reporting for single reportable segment | 8 |
| 4 | Accounts and note receivable | 9 |
| 5 | Inventory | 9 |
| 6 | Property, plant and equipment, net | 10 |
| 7 | Accrued expenses and other current liabilities | 10 |
| 8 | Commitments and contingencies | 11 |
| 9 | Debt | 13 |
| 10 | Equity | 16 |
| 11 | Revenue recognition | 17 |
| 12 | Stock-based compensation | 18 |
| 13 | Income taxes | 20 |
| 14 | Fair value of financial instruments | 21 |
| 15 | Leases | 22 |
| 16 | Related party transactions | 24 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.